Gene therapy to improve migration of T cells to the tumor site.

Antonio Di Stasi, Biagio De Angelis, Barbara Savoldo

Research output: Contribution to journalArticlepeer-review


One requirement for anti-tumor T cells to be effective is their successful traffic to tumor sites. Trafficking of T cells to lymphoid organs and peripheral tissues is a multistage process. Soluble and tissue-bonded chemokines interacting with chemokine receptors expressed by T lymphocytes certainly play a pivotal role in determining migration under physiologic conditions and during inflammation. Therefore a match between the chemokines the tumor produces and the chemokine receptors the effector T cells express is required. Since chemokine produced by the targeted tumor may not match the subset of chemokine receptors expressed by T cells, gene therapy can be used to force the expression of the specific chemokine receptor by effector T cells so that the anti-tumor activity of adoptively transferred anti-tumor T cells is maximized.

Original languageEnglish
Pages (from-to)103-118
Number of pages16
JournalMethods in molecular biology (Clifton, N.J.)
Publication statusPublished - 2010

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Gene therapy to improve migration of T cells to the tumor site.'. Together they form a unique fingerprint.

Cite this